OUTLOOK THERAPEUTICS Ownership
| OTLK Stock | USD 2.01 0.31 18.24% |
Shares in Circulation | First Issued 2014-12-31 | Previous Quarter 14.3 M | Current Value 25.5 M | Avarage Shares Outstanding 5 M | Quarterly Volatility 6.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
OUTLOOK |
OUTLOOK Stock Ownership Analysis
About 36.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.06. OUTLOOK THERAPEUTICS INC last dividend was issued on the 18th of March 2019. The entity had 1:20 split on the 14th of March 2024. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Outlook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. To find out more about OUTLOOK THERAPEUTICS INC contact Russell III at 609 619 3990 or learn more at https://www.outlooktherapeutics.com.OUTLOOK Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OUTLOOK THERAPEUTICS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OUTLOOK THERAPEUTICS INC backward and forwards among themselves. OUTLOOK THERAPEUTICS's institutional investor refers to the entity that pools money to purchase OUTLOOK THERAPEUTICS's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-09-30 | 151.5 K | Northern Trust Corp | 2024-09-30 | 118.9 K | Federated Hermes Inc | 2024-09-30 | 91.4 K | Charles Schwab Investment Management Inc | 2024-09-30 | 51.5 K | Lvw Advisors, Llc | 2024-09-30 | 47.7 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 43.7 K | Susquehanna Fundamental Investments, Llc | 2024-06-30 | 41 K | Xtx Topco Ltd | 2024-09-30 | 37.3 K | Goldman Sachs Group Inc | 2024-09-30 | 35.6 K | Great Point Partners Llc | 2024-06-30 | 1.7 M | Tang Capital Management Llc | 2024-09-30 | 1.6 M |
OUTLOOK THERAPEUTICS INC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OUTLOOK THERAPEUTICS insiders, such as employees or executives, is commonly permitted as long as it does not rely on OUTLOOK THERAPEUTICS's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OUTLOOK THERAPEUTICS insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OUTLOOK THERAPEUTICS Outstanding Bonds
OUTLOOK THERAPEUTICS issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. OUTLOOK THERAPEUTICS INC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most OUTLOOK bonds can be classified according to their maturity, which is the date when OUTLOOK THERAPEUTICS INC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
OUTLOOK THERAPEUTICS Corporate Filings
8K | 27th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 26th of June 2024 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.